A new meta-analysis including some of the more contemporary statin trials has found that the agents significantly improve survival and reduce coronary and cardiovascular end points in primary-prevention populations, a benefit that extends to all subgroups. But the exact cost/benefit equation for each group remains to be determined.
Rotterdam, the Netherlands - Use of statins is associated with significantly improved survival and large reductions in the risk of major cardiovascular events in patients who have risk factors but who do not have established cardiovascular disease, according to a new meta-analysis of major statin trials published online June 30 in BMJ [1].
It shows that the relative risk reduction from long-term statin use in a primary-care setting is comparable to that observed in secondary prevention and confirms the results of the JUPITER study regarding the beneficial effects of statins across a range of patient groups, say the researchers.Read full article »